Want to see IN:APOLLOHOSP full AI Analyst Report?
Top Page
Apollo Hospitals Enterprise Limited
(APOLLOHOSP)
Select Model
Select Model
Rating:59Neutral
Price Target:
₹9,049.00
▲(1.93% Upside)
Action:Reiterated
Date:08/24/26
The score is supported primarily by improving fundamentals (faster revenue growth, expanding margins, and strong ROE), but is held back by premium valuation (high P/E and low yield) and weaker near-term technicals (negative MACD and price below short-term moving averages).
Positive Factors
Accelerating Revenue Growth
Revenue growth accelerated to 8.4% in 2026 from about 0.1% in 2025, extending the multi-year uptrend. Sustained growth can reflect stronger patient volumes and improved absorption of fixed hospital infrastructure, supporting the earnings base.
Negative Factors
Elevated and Rising Leverage
Debt is close to equity and leverage has generally increased since 2023. Because hospital earnings depend on utilization, case mix, and pricing, a higher fixed financing burden could reduce flexibility and amplify pressure during weaker operating periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Revenue growth accelerated to 8.4% in 2026 from about 0.1% in 2025, extending the multi-year uptrend. Sustained growth can reflect stronger patient volumes and improved absorption of fixed hospital infrastructure, supporting the earnings base.
Read all positive factors
Apollo Hospitals Enterprise Limited (APOLLOHOSP) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.26T
Dividend Yield0.23%
Average Volume (3M)32.03K
Price to Earnings (P/E)61.5
Beta (1Y)0.86
Revenue Growth17.20%
EPS Growth32.79%
CountryIN
Employees44,008
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)145.34
Shares Outstanding143,784,650
10 Day Avg. Volume17,721
30 Day Avg. Volume32,033
Financial Highlights & Ratios
PEG Ratio1.60
Price to Book (P/B)11.25
Price to Sales (P/S)4.23
P/FCF Ratio149.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹10,260.00Price Target Upside15.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)171.04
Revenue Forecast (FY)₹300.52B
Apollo Hospitals Enterprise Limited Business Overview & Revenue Model
Company Description
Apollo Hospitals Enterprise Limited, through its group entities, delivers a comprehensive range of medical services both within India and across international borders. Its medical infrastructure spans primary, secondary, and tertiary levels of car...
How the Company Makes Money
Apollo Hospitals Enterprise Limited primarily generates revenue by delivering healthcare services across its hospital network and related healthcare businesses. Key revenue streams include: (1) Hospital services: Income from inpatient and outpatie...
Apollo Hospitals Enterprise Limited Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
70
Positive
Cash Flow
62
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 264.30B | 252.28B | 217.94B | 190.59B | 166.13B | 146.63B |
| Gross Profit | 100.28B | 82.77B | 73.50B | 63.98B | 56.68B | 51.31B |
| EBITDA | 40.72B | 39.87B | 27.98B | 22.11B | 19.11B | 20.45B |
| Net Income | 20.89B | 19.42B | 14.46B | 8.99B | 8.19B | 10.56B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 221.97B | 206.57B | 167.53B | 144.28B | 131.92B |
| Cash, Cash Equivalents and Short-Term Investments | 18.56B | 21.33B | 27.93B | 11.89B | 7.26B | 10.48B |
| Total Debt | 0.00 | 84.93B | 78.64B | 53.33B | 43.32B | 40.68B |
| Total Liabilities | -99.75B | 122.22B | 120.05B | 94.33B | 78.96B | 73.15B |
| Stockholders Equity | 99.75B | 94.80B | 82.12B | 69.35B | 61.97B | 56.23B |
Cash Flow | ||||||
| Free Cash Flow | 6.19B | 7.12B | 2.16B | 7.83B | 2.49B | 9.71B |
| Operating Cash Flow | 13.25B | 26.74B | 19.29B | 19.20B | 13.77B | 16.28B |
| Investing Cash Flow | -10.70B | -22.44B | -34.77B | -15.37B | -8.71B | -8.47B |
| Financing Cash Flow | -3.48B | -2.00B | 16.21B | -3.11B | -6.33B | -7.93B |
Apollo Hospitals Enterprise Limited Technical Analysis
Positive
8878.00
Price Trends
8820.65
Negative
8556.63
Positive
7939.75
Positive
Market Momentum
-5.92
Positive
49.21
Neutral
35.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APOLLOHOSP, the sentiment is Positive. The current price of 8878 is above the 20-day moving average (MA) of 8782.44, above the 50-day MA of 8820.65, and above the 200-day MA of 7939.75, indicating a neutral trend. The MACD of -5.92 indicates Positive momentum. The RSI at 49.21 is Neutral, neither overbought nor oversold. The STOCH value of 35.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:APOLLOHOSP.
Apollo Hospitals Enterprise Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ₹382.62B | 72.43 | ― | 0.07% | 21.27% | 4.09% | |
64 Neutral | ₹662.82B | 122.37 | ― | 0.53% | 15.70% | -2.76% | |
62 Neutral | ₹382.40B | 48.07 | ― | 0.23% | 57.80% | 4.07% | |
60 Neutral | ₹669.84B | 63.83 | ― | 0.11% | 17.50% | 20.65% | |
59 Neutral | ₹1.26T | 61.54 | ― | 0.23% | 17.20% | 32.79% | |
55 Neutral | ₹1.01T | 70.09 | ― | 0.19% | 15.96% | 26.87% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,770.25
981.73
12.60%
IN:ASTERDM
Aster DM Healthcare Ltd.
755.85
104.60
16.06%
IN:FORTIS
Fortis Healthcare Ltd.
875.00
-78.64
-8.25%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,055.00
-103.79
-8.96%
IN:MEDANTA
Global Health Limited
1,506.75
153.13
11.31%
IN:NH
Narayana Hrudayalaya Ltd.
1,929.75
155.69
8.78%
Apollo Hospitals Enterprise Limited Corporate Events
Apollo Hospitals Holds NCLT-Convened Meetings on Group Restructuring Scheme
Jun 24, 2026
Apollo Hospitals Enterprise Limited reported that, pursuant to directions from the National Company Law Tribunal’s Chennai Bench, it held court-convened meetings of its secured creditors, unsecured creditors and equity shareholders on 24 Jun...
Apollo Hospitals holds NCLT-directed meetings on group restructuring scheme
Jun 24, 2026
Apollo Hospitals Enterprise Limited convened court-directed meetings of its secured creditors, unsecured creditors, and equity shareholders on June 24, 2026 via video conferencing and other audio-visual means. The meetings were held to consider an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.